Global Dengue Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dengue Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.
Dengue Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dengue Vaccines market is projected to reach US$ 1033.7 million in 2034, increasing from US$ 400.6 million in 2022, with the CAGR of 14.3% during the period of 2024 to 2034. Demand from Public Sector and Private Sector are the major drivers for the industry.
The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dengue Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Sanofi
Takeda
Segment by Type
Dengvaxia
TAK-003
Others
Public Sector
Private Sector
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dengue Vaccines market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Dengue Vaccines introduction, etc. Dengue Vaccines Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Dengue Vaccines market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Dengue Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dengue Vaccines market is projected to reach US$ 1033.7 million in 2034, increasing from US$ 400.6 million in 2022, with the CAGR of 14.3% during the period of 2024 to 2034. Demand from Public Sector and Private Sector are the major drivers for the industry.
The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dengue Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Sanofi
Takeda
Segment by Type
Dengvaxia
TAK-003
Others
Segment by Application
Public Sector
Private Sector
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dengue Vaccines market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Dengue Vaccines introduction, etc. Dengue Vaccines Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Dengue Vaccines market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices